Data Year:
Select Other Years

For its 2024 fiscal year, AMGEN INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Robert A. Bradway
Chief Executive Officer and President
Total Compensation $24,428,495 View details Pay Rank By Title In Biotechnology industry #11 View more
David M. Reese
Executive Vice President, and Chief Technology Officer
Total Compensation $8,126,822 View details Pay Rank By Title In Biotechnology industry #1 View more
Murdo Gordon
Executive Vice President, Global Commercial Operations
Total Compensation $8,473,500 View details Pay Rank By Title In Biotechnology industry #16 View more
Peter H. Griffith
Executive Vice President and Chief Financial Officer
Total Compensation $7,806,811 View details Pay Rank By Title In Biotechnology industry #20 View more
James E. Bradner
Executive Vice President, Research and Development
Total Compensation $14,914,381 View details Pay Rank By Title In Biotechnology industry #2 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at AMGEN INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. AMGEN INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. AMGEN INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Robert A. Bradway
Chief Executive Officer and President
Total Cash $5,714,242 Equity $17,999,921 Other $714,332 $24,428,495
David M. Reese
Executive Vice President, and Chief Technology Officer
Total Cash $3,008,615 Equity $4,799,597 Other $318,610 $8,126,822
Murdo Gordon
Executive Vice President, Global Commercial Operations
Total Cash $2,839,268 Equity $5,299,470 Other $334,762 $8,473,500
Peter H. Griffith
Executive Vice President and Chief Financial Officer
Total Cash $2,688,633 Equity $4,799,597 Other $318,581 $7,806,811
James E. Bradner
Executive Vice President, Research and Development
Total Cash $3,896,760 Equity $10,818,704 Other $198,917 $14,914,381
For its 2024 fiscal year, AMGEN INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Robert A. Bradway CEO Pay $24,428,495 Median Employee Pay $160,017 CEO Pay Ratio 153:1
For its 2024 fiscal year, AMGEN INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Amy E. Miles Total Cash $360,053
Brian J. Druker Total Cash $372,441
Charles M. Holley, Jr. Total Cash $390,053
Ellen J. Kullman Total Cash $381,734
Greg C. Garland Total Cash $400,053
Mary E. Klotman Total Cash $301,742
Michael V. Drake Total Cash $380,086
R. Sanders Williams Total Cash $59,671
Robert A. Eckert Total Cash $450,067
Ronald D. Sugar Total Cash $68,033
S. Omar Ishrak Total Cash $382,279
Tyler Jacks Total Cash $360,064
Wanda M. Austin Total Cash $370,183
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.